Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
fluconazole + cefazolin
- Development stage
- Unknown
- Lead developer
- Pfizer
- Modality
- Small Molecules
- Administration
- Oral, Intravenous, Intramuscular
01
Overview
A combination of fluconazole, an azole antifungal agent, and a first-generation cephalosporin antibiotic. Fluconazole inhibits fungal cell membrane synthesis by targeting the cytochrome P450 enzyme 14α-demethylase, while cefazolin inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins. This combination provides coverage against both fungal and bacterial infections.
- Other names
- FLU + CZO
02
Targets
CYP51A1 (Sterol 14α-demethylase)PBP1A (Penicillin-binding protein 1A)PBP1b (Penicillin-binding protein 1B)PBP2 (Penicillin-binding protein 2)
Beyond the preview
Go deeper on fluconazole + cefazolin.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on fluconazole + cefazolin.